McNicoll Lewis & Vlak Reaffirms Buy Rating on Affymax (AFFY)
A number of other analysts have also recently weighed in on AFFY. Analysts at Analyst raised their price target on shares of Affymax to $21.00 in a research note to investors on Monday. Separately, analysts at MLV & Co raised their price target on shares of Affymax from $12.00 to $21.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Finally, analysts at Auriga reiterated a “buy” rating on shares of Affymax in a research note to investors on Tuesday, May 8th.
Affymax opened at 14.10 on Monday. Affymax has a 52-week low of $3.93 and a 52-week high of $16.25. The company’s market cap is $509.1 million.
Affymax, Inc. is a biopharmaceutical company developing drugs to improve the treatment of serious and often life-threatening conditions.